Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma
- Author:
Min Ji JEON
1
;
Yea Eun KANG
;
Jae Hoon MOON
;
Dong Jun LIM
;
Chang Yoon LEE
;
Yong Sang LEE
;
Sun Wook KIM
;
Min-Hee KIM
;
Bo Hyun KIM
;
Ho-Cheol KANG
;
Minho SHONG
;
Sun Wook CHO
;
Won Bae KIM
Author Information
- Publication Type:Original Article
- From:Endocrinology and Metabolism 2021;36(2):359-364
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:A Korean Multicenter Prospective cohort study of Active Surveillance or Surgery (KoMPASS) for papillary thyroid microcarcinomas (PTMCs) has been initiated. The aim is to compare clinical outcomes between active surveillance (AS) and an immediate lobectomy for low-risk PTMCs. We here outline the detailed protocol for this study.
Methods:Adult patients with a cytopathologically confirmed PTMC sized 6.0 to 10.0 mm by ultrasound (US) will be included. Patients will be excluded if they have a suspicious extra-thyroidal extension or metastasis of a PTMC or multiple thyroid nodules or other thyroid diseases which require a total thyroidectomy. Printed material describing the prognosis of PTMCs, and the pros and cons of each management option, will be provided to eligible patients to select their preferred intervention. For the AS group, thyroid US, thyroid function, and quality of life (QoL) parameters will be monitored every 6 months during the first year, and then annually thereafter. Disease progression will be defined as a ≥3 mm increase in maximal diameter of a PTMC, or the development of new thyroid cancers or metastases. If progression is detected, patients should undergo appropriate surgery. For the lobectomy group, a lobectomy with prophylactic central neck dissection will be done within 6 months. After initial surgery, thyroid US, thyroid function, serum thyroglobulin (Tg), anti-Tg antibody, and QoL parameters will be monitored every 6 months during the first year and annually thereafter. Disease progression will be defined in these cases as the development of new thyroid cancers or metastases.
Conclusion:KoMPASS findings will help to confirm the role of AS, and develop individualized management strategies, for low-risk PTMCs.
